Myelodysplasia-associated autoimmunity: Clinical and pathophysiologic concepts

European Journal of Clinical Investigation

Volumn 34, Issue 10, 2004, Pages 690-700

  Voulgarelis, M ^a   Giannouli, S ^a   Ritis, K ^b   Tzioufas, A G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Apoptosis; Autoimmune manifestations; Bone marrow failure; Ineffective haemopoiesis; IRF 1; Myelodysplastic syndrome

Indexed keywords

INTERFERON REGULATORY FACTOR 1; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW DEPRESSION; DISEASE ASSOCIATION; HUMAN; IMMUNOPATHOGENESIS; MYELODYSPLASIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

APOPTOSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DNA-BINDING PROTEINS; EXONS; HEMATOPOIESIS; HUMANS; INTERFERON REGULATORY FACTOR-1; MYELODYSPLASTIC SYNDROMES; PHOSPHOPROTEINS; PROGNOSIS; RNA, MESSENGER;

EID: 7044237599     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01417.x     Document Type: Review

References (95)

1. Yoshida Y. Hypothesis: apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993;7:144-6.
2. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268-76.
3. Hellstrom-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997;21:415-25.
4. Raza A, Gregory SA, Preisler HD. The myelodysplastic syndromes in 1996: complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 1996;20:881-90.
5. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997;11:839-45.
6. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996;11:4275-87.
7. Nagler A, Binet C, Mackichan ML, Negrin R, Bangs C, Donlon T et al. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF. Blood 1990;76:1299-307.
8. Parker JE, Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998;10:220-30.
9. Greenberg PL. Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment. Leuk Res 1998;22:1123-36.
10. Claessens YE, Bouscary D, Dupont JM, Picard F, Melle J, Gisselbrecht S et al. In vitro proliferation and differentiation of erythroid progenitors from patients with myelodysplastic syndromes: evidence for Fas-dependent apoptosis. Blood 2002;99:1594-601.
11. Mundle S, Venugopal P, Shetty V, Ali A, Chopra H, Handa H et al. The relative extent and propensity of CD34+ vs. CD34- cells to undergo apoptosis in myelodysplastic marrows. Int J Hematol 1999;69:152-9.
12. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000;96:3932-8.
13. Josefsen D, Myklebust JH, Lynch DH, Stokke T, Blomhoff HK, Smeland EB. Fas ligand promotes cell survival of immature human bone marrow CD34+ CD38- hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol 1999;27:1451-9.
14. Mundle SD, Mativi BY, Bagai K, Feldman G, Cheema P, Gautam U et al. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows. Int J Hematol 1999;70:83-90.
15. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997;89:1854-61.
16. Maurer AB, Ganser A, Buhl R, Seipelt G, Ottmann OG, Mentzel U et al. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia 1993;7:1728-33.
17. Bowen D, Yancik S, Bennett L, Culligan D, Resser K. Serum stem cell factor concentration in patients with myelodysplastic syndromes. Br J Haematol 1993;85:63-6.
18. Fontenay-Roupie M, Bouscary D, Guesnu M, Picard F, Meile J, Lacombe C et al. Ineffective erythropoiesis in myelodysplastic syndromes: correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol 1999;106:464-73.
19. Lepelley P, Grardel N, Erny O, Iaru T, Obein V, Cosson A et al. Fas/APO-1 (CD95) expression in myelodysplastic syndromes. Leuk Lymphoma 1998;30:307-12.
20. Mundle SD, Reza S, Ali A, Mativi Y, Sherry V, Venugopal P et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999;140:201-7.
21. Kitagawa M, Yamaguchi S, Takahashi M, Tanizawa T, Hirokawa K, Kamiyama R. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Leukemia 1998;12:486-92.
22. Sawanobori M, Yamaguchi S, Hasegawa M, Inoue M, Suzuki K, Kamiyama R et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003;27:583-91.
23. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M et al. Overexpression of tumor necrosis factor (TNF) - and interferon (IFN) - by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997;11:2049-54.
24. Maciejewski JP, Selleri C, Anderson S, Young N. Fas antigen expression in CD34+ human bone marrow cells is induced by interferon- and tumor necrosis a and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995;85:3183-90.
25. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A et al. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103:176-88.
26. Sherry V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996;20:891-900.
27. Dar S, Mundle S, Andric T, Qawi H, Shetty V, Reza S et al. Biological characteristics of myelodysplastic syndrome patients who demonstrated high versus no intramedullary apoptosis. Eur J Haematol 1999;62:90-4.
28. Verhoef GE, De Schouwer P, Ceuppens JL, Van Damme J, Goossens W, Boogaerts MA. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia 1992;6:1268-72.
29. Musto P, Matera R, Minervini MM, Checchia-de Ambrosio C, Bodenizza C, Falcone A et al. Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin. Haematologica 1994;79:265-8.
30. Raza A, Mundle S, Sherry V, Alvi S, Chopra H, Span L et al. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines. Int J Hematol 1996;63:265-78.
31. Peddie CM, Wolf CR, McLellan LI, Collins AR, Bowen DT. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997;99:625-31.
32. Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J Exp Med 1997;185:1511-6.
33. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F et al. Fas ligand in human serum. Nat Med 1996;2:317-22.
34. Krammer PH, Dhein J, Walczak H, Behrmann I, Mariani S, Matiba B et al. The role of APO-1-mediated apoptosis in the immune system. Immunol Rev 1994;142:175-91.
35. De Maria R, Testa U, Luchetti L, Zeuner A, Stassi G, Pelosi E et al. Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood 1999;93:796-803.
36. Dai CH, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 1998;91:1235-42.
37. Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR. Fc) in patients with low risk myelodysplastic syndrome. Leuk Res 2002;26:721-4.
38. Coutinho LH, Geary CG, Chang J, Harrison C, Testa NG. Functional studies of bone marrow haemopoietic and stromal cells in the myelodysplastic syndrome (MDS). Br J Haematol 1990;75:16-25.
39. Aizawa S, Nakano M, Iwase O, Yaguchi M, Hiramoto M, Hoshi H et al. Bone marrow stroma from refractory anemia of myelodysplastic syndrome is defective in its ability to support normal CD34-positive cell proliferation and differentiation in vitro. Leuk Res 1999;23:239-46.
40. Deeg HJ, Beckham C, Loken MR, Bryant E, Lesnikova M, Shulman HM et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma 2000;37:405-14.
41. Bogdanovic Ad Trpinac DP, Jankovic GM, Bumbasirevic VZ, Obradovic M, Colovic MD. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 2001;11:656-9.
42. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001;98:3058-65.
43. Barren J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000;37:15-29.
44. Parker JE, Fishlock KL, Mijovic A, Czepulkowski B, Pagliuca A, Mufti GJ. Low-risk myelodysplastic syndromes is associated with excessive apoptosis and an increased ratio of pro-versus anti-apoptotic bcl-2-related proteins. Br J Haematol 1998;103:1075-82.
45. Sloand EM, Kim S, Fuhrer M, Risitano AM, Nakamura R, Maciejewski JP et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002;100:4427-32.
46. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barren AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997;99:690-705.
47. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003;120:679-84.
48. Smith MA, Smith JG. The occurrence subtype and significance of haemopoietic inhibitory T cells (HIT cells) in myelodysplasia: an in vitro study. Leuk Res 1991;15:597-601.
49. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, Mavroudis D, Hensel N, Barrett AJ. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998;102 (5):1314-22.
50. Hamann D, Roos MT, van Lier RA. Faces and phases of human CD8 T-cell development. Immunol Today 1999;20:177-80.
51. Melenhorst JJ, Eniafe R, Follmann D, Nakamura R, Kirby M, Barren AJ. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002;119:97-105.
52. Epperson DE, Nakamura R, Saunthararajah Y, Melenhorst J, Barrett AJ. Oligoclonal T cell expansion in myelodysplastic syndrome: evidence for an autoimmune process. Leuk Res 2001;25:1075-83.
53. Matsutani T, Yoshioka T, Tsuruta Y, Shimamoto T, Ohyashiki JH, Suzuki R et al. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 2003;27:305-12.
54. Kook H, Zeng W, Guibin C, Kirby M, Young NS, Maciejewski JP. Increased cytotoxic T cells with effector phenotype in aplastic anemia and myelodysplasia. Exp Hematol 2001;29:1270-7.
55. Culligan DJ, Cachia P, Whittaker J, Jacobs A, Padua RA. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 1992;81:346-52.
56. Kroef MJ, Fibbe WE, Mout R, Jansen RP, Haak HL, Wessels JW et al. Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions. Blood 1993;8:1849-54.
57. Kibbelaar RE, van Kamp H, Dreef EJ, de Groot-Swings G, Kluin-Nelemans JC, Beverstock GC et al. Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes. Blood 1992;79:1823-8.
58. Melenhorst JJ, Fibbe WE, Smits S, Willemze R, Landegent JE. Aplastic anaemia patients with clonal X-chromosome inactivation pattern in haemopoietic cells exhibit polyclonal TCRgamma and IgH gene rearrangements. Br J Haematol 1996;93:326-32.
59. Maciejewski JP, Hibbs JR, Anderson S, Katevas P, Young NS. Bone marrow and peripheral blood lymphocyte phenotype in patients with bone marrow failure. Exp Hematol 1994;22:1102-10.
60. Melenhorst JJ, van Luxemburg-Heijs SA, Landegent JE, Willemze R, Fibbe WE, Falkenburg JH. Aplastic anaemia in donor cells 14 years after bone-marrow transplant. Lancet 1999;353:2037-8.
61. Dietrich PY, Caignard A, Lim A, Chung V, Pico JL, Pannetier C et al. In vivo T-cell clonal amplification at time of acute graft-versus-host disease. Blood 1994;84:2815-20.
62. Hong J, Zang YC, Tejada-Simon MV, Kozovska M, Li S, Singh RA et al. A common TCR V-D-J sequence in V beta 13-1 T cells recognizing an immunodominant peptide of myelin basic protein in multiple sclerosis. J Immunol 1999;163:3530-8.
63. Mima T, Ohshima S, Sasai M, Nishioka K, Shimizu M, Murata N et al. Dominant and shared T cell receptor beta chain variable regions of T cells inducing synovial hyperplasia in rheumatoid arthritis. Biochem Biophys Res Commun 1999;263:172-80.
64. Raza A. Hypothesis: myelodysplastic syndromes may have a viral etiology. Int J Hematol 1998;68:245-56.
65. Kochenderfer JN, Kobayashi S, Wieder ED, Su C, Molldrem JJ. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002;100:3639-45.
66. Martinez-Jaramillo G, Flores-Figueroa E, Gomez-Morales E, Sanchez-Valle E, Mayani H. Tumor necrosis factor-alpha levels in long-term marrow cultures from patients with aplastic anemia: modulation by granulocyte-macrophage colony-stimulating factor. Am J Hematol 2001;68:144-8.
67. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997;336:1365-72.
68. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D, Young NS. Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 2002;100:1185-91.
69. Zeng W, Nakao S, Takamatsu H, Yachie A, Takami A, Kondo Y et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood 1999;93:3008-16.
70. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996;33:150-62.
71. Enright H, Jacob HS, Vercellotti G, Howe R, Beizer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995;91:403-8.
72. Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1991;18:721-7.
73. Billstrom R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes-clinical and cytogenetic features. Eur J Haematol 1995;55:42-8.
74. Okamoto T, Okada M, Mori A, Saheki K, Takatsuka H, Wada H et al. Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients. Int J Hematol 1997;66:345-51.
75. Mufti GJ, Figes A, Hamblin TJ, Oscier DG, Copplestone JA. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986;63:143-7.
76. Economopoulos T, Economidou J, Giannopoulos G, Terzoglou C, Papageorgiou E, Dervenoulas J et al. Immune abnormalities in myelodysplastic syndromes. J Clin Pathol 1985;38:908-11.
77. Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxf) 2004;43:626-32.
78. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-99.
79. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
80. Fujita T, Sakakibara J, Sudo Y, Miyamoto M, Kimura Y, Taniguchi T. Evidence for a nuclear factor (s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements. EMBO J 1988;7:3397-405.
81. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 1988;54:903-13.
82. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994;77:829-39.
83. Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S, Affabris E. IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res 2002;22:39-47.
84. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML et al. Deletion of IRF-1, mapping to chromosome 5q31 · 1, in human leukemia and preleukemic myelodysplasia. Science 1993;259:968-71.
85. Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N et al. Accelerated exon skipping of IRF-1mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 1994;9:3313-20.
86. Ogasawara K, Hida S, Azimi N, Tagaya Y, Sato T, Yokochi-Fukuda T et al. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 1998;391:700-3.
87. Kroger A, Koster M, Schroeder K, Hauser H, Mueller PP. Activities of IRF-1. J Interferon Cytokine Res 2002;22:5-14.
88. Salkowski CA, Kopydlowski K, Blanco J, Cody MJ, McNally R, Vogel SN. IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice. J Immunol 1999;163:1529-36.
89. Blanco JC, Contursi C, Salkowski CA, DeWitt DL, Ozato K, Vogel SN. Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression. J Exp Med 2000;191:2131-44.
90. Giannouli S, Tzoanopoulos D, Ritis K, Kartalis G, Moutsopoulos HM, Voulgarelis M. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann Rheum Dis 2004;63:578-82.
91. Lechleitner S, Gille J, Johnson DR, Petzelbauer P. Interferon enhances tumor necrosis factor-induced vascular cell adhesion molecule 1 (CD106) expression in human endothelial cells by an interferon-related factor 1-dependent pathway. J Exp Med 1998;187:2023-30.
92. Coll-Vinent B, Cebrian M, Cid MC, Font C, Esparza J, Juan M et al. Dynamic pattern of endothelial cell adhension molecule expression in muscle and perineural vessels from patients with classic polyarteritis nodosa. Arthritis Rheum 1998;41:435-44.
93. Cid MC, Cebrian M, Font C, Coll-Vinent B, Hernandez-Rodriguez J, Esparza J et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 2000;43:184-94.
94. Tada Y, Ho A, Matsuyama T, Mak TW. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J Exp Med 1997;185:231-8.
95. Hamidou MA, Boumalassa A, Larroche C, El Kouri D, Bletry O, Grolleau JY. Systemic medium-sized vessel vasculitis associated with chronic myelomonocytic leukemia. Semin Arthritis Rheum 2001;31:119-26.